Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma
Alexandra Pender,1 Robin L Jones1,2 1Sarcoma Unit, Department of Medicine, The Royal Marsden NHS Foundation Trust, 2Division of Clinical Studies, The Institute of Cancer Research, London, UK Abstract: The outcome of patients with unresectable or metastatic soft tissue sarcoma (STS) remains poor with...
Guardado en:
Autores principales: | Pender A, Jones RL |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/61c57060328d44beabb0ff5b9876a106 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?
por: Kyriazoglou A, et al.
Publicado: (2020) -
Involvement of PAR2 in platelet‐derived growth factor receptor‐α‐positive cell proliferation in the colon of diabetic mice
por: Yu‐Jia Li, et al.
Publicado: (2021) -
Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2
por: Simone Romagnoli, et al.
Publicado: (2021) -
Demographics, Changes in Treatment Patterns, and Outcomes of Bone and Soft Tissue Sarcomas in Korea—A Sarcoma-Specific, Institutional Registry-Based Analysis
por: Jeong H, et al.
Publicado: (2021) -
Expression of Platelet Derived Growth Factor a, Its Receptor, and Integrin Subunit Alpha V in Feline Injection-Site Sarcomas
por: Ahmed Ishtiaq, et al.
Publicado: (2021)